A Year In Review
The bispecific field is expanding fast, with 3,162 drugs now in development—a 32% increase from last year. In 2024, clinical momentum surged, with a record 608 new trials initiated, highlighting growing confidence in this space.
This report covers key approvals, emerging trial trends, regulatory updates, and investment shifts, giving you the insights needed to stay ahead.
Download Now
Lead the future of bispecific innovation!
The Review delivers critical insights into the latest innovations, from novel therapeutic formats to strategic industry moves. Explore groundbreaking clinical developments, commercial trends, and the evolving regulatory environment shaping the future of bispecifics.
Report Contents
The Drug Landscape
An overview of clinical entries, discontinuations, and top targets at each phase. Plus insights into new scaffold formats, and emerging therapeutic classes.
The Trial Landscape
A breakdown of 608 new bispecific trials, covering phase distribution, disease indications, and trial locations.
The Commercial Market
2024’s deal and company activity, with a spotlight on the top 10 highest-value deals and emerging industry players.
The Future of Bispecifics
A look ahead at 2025’s potential approvals and the number of trials set to conclude over the next decade, shaping the future of bispecific innovation.
Regulatory Announcements
A summary of 2024’s regulatory updates by type, with a look at the top 5 drugs with the most regulatory activity.
Previous Bispecific Landscape Reviews
ADC 2024 H1 Landscape Review
An analysis of the ADC landscape in H1 of 2024
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
